A Phase 1 study to test the safety of an oral investigational drug (either AG-120 or AG-221) in combination with standard chemotherapeutic treatment for patients newly diagnosed with a blood malignancy (AML) with an IDH1 mutation and/or IDH2 mutation
AG120-221-C-001
Phase 1 other active
Quick answer
A Phase 1 study to test the safety of an oral investigational drug (either AG-120 or AG-221) in combination with standard chemotherapeutic treatment for patients newly diagnosed with a blood malignancy (AML) with an IDH1 mutation and/or IDH2 mutation for Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2 Mutation is a Phase 1 program (other) at The George Institute with 1 ClinicalTrials.gov record(s).
Program details
- Company
- The George Institute
- Indication
- Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2 Mutation
- Phase
- Phase 1
- Modality
- other
- Status
- active